The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3579-3590

  Raha, Debasish ^a   Wilson, Timothy R ^a   Peng, Jing ^b   Peterson, David ^b   Yue, Peng ^c   Evangelista, Marie ^a   Wilson, Catherine ^a   Merchant, Mark ^a   Settleman, Jeff ^a,c  

^a Departments of 1Discovery Oncology   (United States)

^b Translational Oncology   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CRIZOTINIB; DISULFIRAM; ERLOTINIB; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER STEM CELL; CELL PROTECTION; CELL SUBPOPULATION; CONTROLLED STUDY; DNA DAMAGE; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ALDEHYDE DEHYDROGENASE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DISULFIRAM; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; QUINAZOLINES; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85047688749     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3456     Document Type: Article

References (40)

1. Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011;3:623-36.
2. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21: 3214-31.
3. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-64.
4. Singh A, Settleman J. EMT, Cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741- 51.
5. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
6. Holohan C, Schaeybroeck SV, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;10:714-26.
7. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794-8.
8. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003;101: 4098-104.
9. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777-85.
10. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
11. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
12. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis 2001;27:206-16.
13. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, et al. b-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010;18:606-18.
14. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notchand hedgehog-dependent tumor-initiating cells. Cancer Cell 2012;22: 373-88.
15. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133(φ) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 2010;289:151-60.
16. Auvinen P, Tammi R, Tammi M, Johansson R, Kosma VM. Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 2005;4:420-8.
17. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67.
18. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-51.
19. Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 2010;9:2450-7.
20. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011;10:1378-84.
21. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009;15:4234-41.
22. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S , et al. A chromatin-mediated reversible drug tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
23. Wilson TR, Lee DY, Berry L, Shames DS, Settleman, J. Neuregulin-1- mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011;20:158-72.
24. Pinheiro J, Bates D, DebRoy S, Sarkar Dand R Core Team. nlme: linear and nonlinear mixed effects models. R package, version 3.1 96 2014. Available from http://cranr-project.org/packagenlme.
25. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2008. ISBN 3 900051 07 0. Available from http://wwwRproject.org.
26. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, LudemanSM, et al.Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 1999;96:9118-9123.
27. Levi BP, Yilmaz OH, Duester G, Morrison SJ. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood 2009;113:1670-80.
28. Moore SA, Baker HM, Blythe TJ, Kitson KE, Kitson TM, Baker EN. Sheep liver cytosolic aldehyde dehydrogenase: the structure reveals the basis for the retinal specificity of class 1 aldehyde dehydrogenases. Structure 1998;6:1541-51.
29. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO , et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev 2012;64:520-39.
30. Rekha GK, Sladek NE. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Adv Exp Med Biol 1997;414:133-46.
31. Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012;2012:1-21.
32. Choi J, Liu RM, Forman HJ. Adaptation to oxidative stress: quinonemediated protection of signaling in rat lung epithelial L2 cells. Biochem Pharmacol 1997;53:987-93.
33. Blanpain C, Mohrin M, Sotiropoulou PA, Passegue E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 2011;8:16-29.
34. Singh S, Brocker C, Koppaka V, Chen Y, Jackson BC, Matsumoto A, et al. Aldehyde dehydrogenases in cellular responses to oxidative/ electrophilic stress. Free Radic Biol Med 2013;56:89-101.
35. Moreb JS, Mohuczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4- hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 2007; 59:127-36.
36. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M , et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011;29:32-45.
37. Sauna ZE, Peng X-H, Nandigama K, Tekle S, Ambudkar SV. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol 2004;65:675-684.
38. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used antialcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006;66:10425-10433.
39. Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer 2013;109:1876-1885.
40. Dufour P, Lang JM, Giron C, Duclos B, Haehnel P, Jaeck D, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy 1993;6:9-12.